---
title: "PanChol phase 1 booster study: durability after one dose and safety/immunogenicity of a second ora"
id: "medrxiv-11-phase-1-durability-study-of-a-single-dose-of-the-live-attenuated-cholera"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-phase-1-durability-study-of-a-single-dose-of-the-live-attenuated-cholera"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.13.26365415v1?rss=1"
published_at: "2026-10-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PanChol phase 1 booster study: durability after one dose and safety/immunogenicity of a second ora
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-phase-1-durability-study-of-a-single-dose-of-the-live-attenuated-cholera
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.13.26365415v1?rss=1)
- **Published At:** 2026-10-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Open-label phase 1a booster study assessed durability of a single oral dose of the live-attenuated cholera vaccine **PanChol** and safety/immunogenicity of a second dose in adults previously dosed 322–1111 days earlier. - Participants: 20 healthy adults aged 18–55 who had received a prior PanChol dose ranging from 10^5–10^10 CFU; median age 43.6 years. - Intervention: All enrolled participants received a booster dose of 2×10^7 CFU; primary outcome was safety (solicited, unsolicited, serious adverse events). - Immunogenicity endpoints: pre- and post-boost serum **vibriocidal** titers to **Inaba** and **Ogawa**, including seroconversion defined as a ≥4-fold rise from baseline. - Mucosal immunity proxy: quantitative and qualitative stool cultures to measure PanChol shedding after booster versus after the first dose; comparisons used to infer intestinal colonization and mucosal protection. - Safety findings: 9 of 20 (45%) reported at least one solicited adverse event; most events (93% of solicited) were mild and transient; most unsolicited events were mild with one grade 3 event judged unrelated; two unsolicited events were deemed related and were transient. - Immunogenicity results: on day of boosting, 85% had Inaba titers above pre-primary baseline and 70% had Ogawa titers above baseline; 15 of 20 (75%) seroconverted to both serotypes after the boost. - Shedding results: 17 of 20 (85%) had no or self-limited shedding after the boost compared with 10% after the first dose; investigators interpreted reduced shedding after boosting as evidence that a single PanChol dose elicits durable intestinal immunity. - Trial registration: ClinicalTrials.gov NCT05657782; study completed. - Funding and disclosures: Funded by the Wellcome Trust; one author is an inventor on a PanChol patent; other disclosures listed in the source.
## Clinical Analysis & Structured Key Points
Phase 1 durability study of a single dose of the live-attenuated cholera vaccine PanChol and the safety and immunogenicity of a second dose | medRxiv Skip to main content Phase 1 durability study of a single dose of the live-attenuated cholera vaccine PanChol and the safety and immunogenicity of a second dose Deborah R Leitner , View ORCID Profile Stephen R Walsh , Amy C Sherman , Alisse Hannaford , Sudhir Doranga , Masataka Suzuki , George I Balazs , Elliot Hammerness , Kaylee T Nguyen , Natalie E Izaguirre , Akash R Sinha , Mariana I Haugh-Klockner , Alexandra Tong , Xiaofang Li , Damien M Slater , Nirajan Puri , Jason B Harris , Steven Piantadosi , Lindsey R Baden , Matthew K Waldor doi: https://doi.org/10.64898/2026.10.13.26365415 Deborah R Leitner 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: dleitner022{at}gmail.com Stephen R Walsh 2 Brigham & Women's Hospital Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stephen R Walsh Amy C Sherman 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alisse Hannaford 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sudhir Doranga 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Masataka Suzuki 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site George I Balazs 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elliot Hammerness 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kaylee T Nguyen 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Natalie E Izaguirre 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Akash R Sinha 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mariana I Haugh-Klockner 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alexandra Tong 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Xiaofang Li 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Damien M Slater 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nirajan Puri 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jason B Harris 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Steven Piantadosi 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lindsey R Baden 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Matthew K Waldor 1 Mass General Brigham Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background Killed whole–cell oral cholera vaccines require multiple doses and have reduced efficacy in young children, limiting their utility. PanChol is a single–dose, oral live–attenuated cholera vaccine engineered from a current seventh pandemic El Tor O1 Vibrio cholerae strain. PanChol was shown to be safe and immunogenic in a previous phase 1a trial. In participants from this first–in–human trial, we aimed to assess the durability of the initial PanChol dose and the safety and immunogenicity of a second dose. Methods This open–label phase 1a booster study was conducted at Brigham and Women′s Hospital (Boston, MA). Eligible participants were healthy adults aged 18–55 years without a history of cholera or gastrointestinal disorders and had received a PanChol dose ranging from 10 5 –10 10 colony–forming units (CFU) within the previous 322–1111 days. All participants received a booster dose of 2x10 7 CFU. The primary outcome was safety, including solicited, unsolicited, and serious adverse events following the second dose of PanChol. Secondary endpoints were the magnitude of pre– and post–vaccination serum vibriocidal titers to both Inaba and Ogawa V. cholerae , including seroconversion (4–fold rise in titers over baseline), and stool shedding of PanChol organisms using quantitative and qualitative stool cultures. Comparisons of the amount of vaccine shedding in stool following primary and secondary immunization were used to assess the intestinal mucosal immunity elicited by the initial PanChol dose. All outcomes were assessed in all participants. This trial is registered with ClinicalTrials.gov, NCT05657782 , and is complete. Findings Between Aug 25, 2025, and Feb 20, 2026, 20 healthy adults who previously received a single oral dose of PanChol were enrolled to receive a booster dose of 2x10 7 CFU. Eleven (55%) of 20 participants were male and the median age was 43·6 (IQR 30·2–49·5). Ten (50%) were White and 17 (85%) were not Hispanic or Latino. Nine (45%) of 20 boost recipients reported at least one solicited adverse event; 13 (93%) of 14 events were mild, and all were transient. The most common solicited adverse event was nausea, reported by 4 (20%) participants; all cases were mild. Most unsolicited adverse events were mild; one was grade 3 and was deemed unrelated to vaccination. Two unsolicited adverse events were deemed related to vaccination (mild gassy sensation and heartburn, both of which occurred on day 1 and resolved the same day). In most participants, vibriocidal antibody titers measured on the day of boosting exceeded baseline titers prior to the initial dose (17 (85%) for Inaba and 14 (70%) for Ogawa). Fifteen (75%) of 20 boost recipients seroconverted vibriocidal antibody titers to both serotypes. After the boost, 17 (85%) participants had no or self–limited vaccine shedding, compared with 10% after the first PanChol dose. Interpretation A second oral dose of PanChol had a favorable safety profile and induced vibriocidal seroconversion to both serotypes in 75% of boost recipients. Intestinal colonization of PanChol following the boost serves as a proxy for measuring mucosal immunity targeting V. cholerae . The decrease in in the abundance of PanChol fecal shedding following the second dose, compared with the first, suggests that a single dose of PanChol is sufficient to confer durable protective immunity against a cholera challenge. These observations underscore the need for further clinical development of PanChol. Funding Wellcome Trust. Competing Interest Statement MKW is an inventor on a patent related to PanChol. SRW has received institutional grants or contracts from Sanofi Pasteur, Janssen Vaccines/Johnson & Johnson, Moderna Tx, Pfizer, AbbVie, F2G, Hookipa, Vir Biotechnology, and Worcester HIV Vaccine; has participated on data safety monitoring or advisory boards for Janssen Vaccines/Johnson & Johnson, CyanVac, CSL Behring, and BioNTech; and his spouse holds stock/stock options in Regeneron Pharmaceuticals. ACS reports consulting fees from Bain Capital and Pfizer. All other authors declare no competing interests. Clinical Trial NCT05657782 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of Mass General Brigham gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability De-identified individual participant data and the data dictionary, or supporting clinical documents, will be made available upon request to the corresponding author after publication for at least five years. Proposals will undergo a scientific review by the PanChol protocol team, require a signed data access agreement and may involve institutional ethics committee review. Funder Information Declared Wellcome Trust, https://ror.org/029chgv08 , 218443/Z/19/Z NIH Common Fund, https://ror.org/001d55x84 , RO1AI042347-30 Howard Hughes Medical Institute, https://ror.org/006w34k90 NIAID , 5-UM1-AI-069412-19 Harvard Clinical and Translational Science Center , 1UL1TR002541-01 NIH Common Fund, https://ror.org/001d55x84 , 1K23AI185318-01A1 NIAID , R01AI179917 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted October 14, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Phase 1 durability study of a single dose of the live-attenuated cholera vaccine PanChol and the safety and immunogenicity of a second dose Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Phase 1 durability study of a single dose of the live-attenuated cholera vaccine PanChol and the safety and immunogenicity of a second dose Deborah R Leitner , Stephen R Walsh , Amy C Sherman , Alisse Hannaford , Sudhir Doranga , Masataka Suzuki , George I Balazs , Elliot Hammerness , Kaylee T Nguyen , Natalie E Izaguirre , Akash R Sinha , Mariana I Haugh-Klockner , Alexandra Tong , Xiaofang Li , Damien M Slater , Nirajan Puri , Jason B Harris , Steven Piantadosi , Lindsey R Baden , Matthew K Waldor medRxiv 2026.10.13.26365415; doi: https://doi.org/10.64898/2026.10.13.26365415 Share This Article: Copy Citation Tools Phase 1 durability study of a single dose of the live-attenuated cholera vaccine PanChol and the safety and immunogenicity of a second dose Deborah R Leitner , Stephen R Walsh , Amy C Sherman , Alisse Hannaford , Sudhir Doranga , Masataka Suzuki , George I Balazs , Elliot Hammerness , Kaylee T Nguyen , Natalie E Izaguirre , Akash R Sinha , Mariana I Haugh-Klockner , Alexandra Tong , Xiaofang Li , Damien M Slater , Nirajan Puri , Jason B Harris , Steven Piantadosi , Lindsey R Baden , Matthew K Waldor medRxiv 2026.10.13.26365415; doi: https://doi.org/10.64898/2026.10.13.26365415 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (628) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4923) Dentistry and Oral Medicine (488) Dermatology (421) Emergency Medicine (667) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1655) Epidemiology (16115) Forensic Medicine (35) Gastroenterology (1227) Genetic and Genomic Medicine (7167) Geriatric Medicine (740) Health Economics (1079) Health Informatics (5179) Health Policy (1452) Health Systems and Quality Improvement (1807) Hematology (595) HIV/AIDS (1362) Infectious Diseases (except HIV/AIDS) (16395) Intensive Care and Critical Care Medicine (1187) Medical Education (684) Medical Ethics (156) Nephrology (733) Neurology (7434) Nursing (372) Nutrition (1110) Obstetrics and Gynecology (1274) Occupational and Environmental Health (1020) Oncology (3686) Ophthalmology (1077) Orthopedics (400) Otolaryngology (461) Pain Medicine (488) Palliative Medicine (142) Pathology (714) Pediatrics (1837) Pharmacology and Therapeutics (744) Primary Care Research (780) Psychiatry and Clinical Psychology (6030) Public and Global Health (9882) Radiology and Imaging (2479) Rehabilitation Medicine and Physical Therapy (1494) Respiratory Medicine (1258) Rheumatology (654) Sexual and Reproductive Health (791) Sports Medicine (591) Surgery (792) Toxicology (109) Transplantation (313) Urology (299)
## Related Clinical Research

- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Self-reported tuberculosis prevalence and vulnerability factors in six rural Indian districts](https://medichelpline.com/clinical-feed/plos-one-16-self-reported-prevalence-of-tuberculosis-and-selected-associated-vulnerability.md)
- [Augmented Trials Mixing Randomized and Observational Data for Postnatal HIV Prophylaxis](https://medichelpline.com/clinical-feed/medrxiv-1-combining-randomized-and-observational-data-the-case-of-postnatal-prophylaxis.md)
- [Readiness for long-acting injectable HIV treatment and PrEP among Ugandan clinic clients](https://medichelpline.com/clinical-feed/medrxiv-7-readiness-to-start-long-acting-injectable-hiv-treatment-and-prevention-and.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.